Interventional × Hematologic Neoplasms × Sarcoma × Clear all
NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
NCT06582849 2025-08-26

EARN

Washington University School of Medicine

Phase NA Completed
33 enrolled
NCT02988466 2025-05-28

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
78 enrolled 16 charts
NCT01474681 2020-12-30

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Novartis

Phase 1/2 Completed
27 enrolled 15 charts
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
NCT02118311 2017-12-02

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
NCT02259348 2017-05-30

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

St. Jude Children's Research Hospital

Phase 2 Terminated
12 enrolled 12 charts
NCT00049504 2017-05-17

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
53 enrolled 10 charts
NCT01621477 2017-02-20

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

St. Jude Children's Research Hospital

Phase 2 Terminated
34 enrolled 12 charts
NCT00514722 2013-08-14

Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies

University of California, San Francisco

Phase NA Terminated
4 enrolled